A roadmap to strengthen standardisation efforts in risk governance of nanotechnology

A roadmap was developed to strengthen standardisation activities for risk governance of nanotechnology. Its baseline is the available standardised and harmonised methods for nanotechnology developed by the International Organization for Standardization (ISO), the European Committee for Standardization (CEN), and the Organisation for Economic Co-operation and Development (OECD). In order to identify improvements and needs for new themes in standardisation work, an analysis of the state-of-the-art concepts and interpretations of risk governance of nanotechnology was performed. Eleven overall areas of action were identified, each including a subset of specific topics. Themes addressed include physical chemical characterisation, assessment of hazard, exposure, risk and socio-economic factors, as well as education & training and social dialogue. This has been visualised in a standardisation roadmap spanning a timeframe of ten years and including key outcomes and highlights of the analysis. Furthermore, the roadmap indicates potential areas of action for harmonisation and standardisation (H&S) for nanomaterials and nanotechnology. It also includes an evaluation of the current level (limited, moderate, intense) of ongoing H&S activities and indicates the time horizon for the different areas of action. As the identified areas differ in their state of development, the number and type of actions varied widely amongst the different actions towards achieving standardisation. Thus, priority areas were also identified. The overall objective of these actions is to strengthen risk governance towards a safe use of nanomaterials and nano-related products. Though not explicitly addressed, risk-based legislation and policies are supported via the proposed H&S actions.

Safe(r) by design guidelines for the nanotechnology industry

Expectations for safer and sustainable chemicals and products are growing to comply with the United Nations and European strategies for sustainability. The application of Safe(r) by Design (SbD) in nanotechnology implies an iterative process where functionality, human health and safety, environmental and economic impact and cost are assessed and balanced as early as possible in the innovation process and updated at each step. The EU H2020 NanoReg2 project was the first European project to implement SbD in six companies handling and/or manufacturing nanomaterials (NMs) and nano-enabled products (NEP). The results from this experience have been used to develop these guidelines on the practical application of SbD. The SbD approach foresees the identification, estimation, and reduction of human and environmental risks as early as possible in the development of a NM or NEP, and it is based on three pillars: (i) safer NMs and NEP; (ii) safer use and end of life and (iii) safer industrial production. The presented guidelines include a set of information and tools that will help deciding at each step of the innovation process whether to continue, apply SbD measures or carry out further tests to reduce uncertainty. It does not intend to be a prescriptive protocol where all suggested steps have to be followed to achieve a SbD NM/NEP or process. Rather, the guidelines are designed to identify risks at an early state and information to be considered to identify those risks. Each company adapts the approach to its specific needs and circumstances as company decisions influence the way forward.

Integrative approach in a safe by design context combining risk, life cycle and socio-economic assessment for safer and sustainable nanomaterials

Moving towards safe and sustainable innovations is an international policy ambition. In the on-hand manuscript, a concept combining safe by design and sustainability was implemented through the integration of human and environmental risk assessment, life cycle assessment as well as an assessment of the economic viability. The result is a nested and iterative process in form of a decision tree that integrates these three elements in order to achieve sustainable, safe and competitive materials, products or services. This approach, embedded into the stage-gate-model for safe by design, allows to reduce the uncertainty related to the assessment of risks and impacts by improving the quality of the data collected along each stage. In the second part of the manuscript, the application is shown for a case study dealing with the application of nanoparticles for Li-Ion batteries. One of the general conclusions out of this case study is that data gaps are a key aspect in view of the reliability of the results.

Blueprint for a self-sustained European Centre for service provision in safe and sustainable innovation for nanotechnology

The coming years are expected to bring rapid changes in the nanotechnology regulatory landscape, with the establishment of a new framework for nano-risk governance, in silico approaches for characterisation and risk assessment of nanomaterials, and novel procedures for the early identification and management of nanomaterial risks. In this context, Safe(r)-by-Design (SbD) emerges as a powerful preventive approach to support the development of safe and sustainable (SSbD) nanotechnology-based products and processes throughout the life cycle. This paper summarises the work undertaken to develop a blueprint for the deployment and operation of a permanent European Centre of collaborating laboratories and research organisations supporting safe innovation in nanotechnologies. The proposed entity, referred to as "the Centre", will establish a 'one-stop shop' for nanosafety-related services and a central contact point for addressing stakeholder questions about nanosafety. Its operation will rely on significant business, legal and market knowledge, as well as other tools developed and acquired through the EU-funded EC4SafeNano project and subsequent ongoing activities. The proposed blueprint adopts a demand-driven service update scheme to allow the necessary vigilance and flexibility to identify opportunities and adjust its activities and services in the rapidly evolving regulatory and nano risk governance landscape. The proposed Centre will play a major role as a conduit to transfer scientific knowledge between the research and commercial laboratories or consultants able to provide high quality nanosafety services, and the end-users of such services (e.g., industry, SMEs, consultancy firms, and regulatory authorities). The Centre will harmonise service provision, and bring novel risk assessment and management approaches, e.g. in silico methodologies, closer to practice, notably through SbD/SSbD, and decisively support safe and sustainable innovation of industrial production in the nanotechnology industry according to the European Chemicals Strategy for Sustainability.

Risk Management Framework for Nano-Biomaterials Used in Medical Devices and Advanced Therapy Medicinal Products

The convergence of nanotechnology and biotechnology has led to substantial advancements in nano-biomaterials (NBMs) used in medical devices (MD) and advanced therapy medicinal products (ATMP). However, there are concerns that applications of NBMs for medical diagnostics, therapeutics and regenerative medicine could also pose health and/or environmental risks since the current understanding of their safety is incomplete. A scientific strategy is therefore needed to assess all risks emerging along the life cycles of these products. To address this need, an overarching risk management framework (RMF) for NBMs used in MD and ATMP is presented in this paper, as a result of a collaborative effort of a team of experts within the EU Project BIORIMA and with relevant inputs from external stakeholders. The framework, in line with current regulatory requirements, is designed according to state-of-the-art approaches to risk assessment and management of both nanomaterials and biomaterials. The collection/generation of data for NBMs safety assessment is based on innovative integrated approaches to testing and assessment (IATA). The framework can support stakeholders (e.g., manufacturers, regulators, consultants) in systematically assessing not only patient safety but also occupational (including healthcare workers) and environmental risks along the life cycle of MD and ATMP. The outputs of the framework enable the user to identify suitable safe(r)-by-design alternatives and/or risk management measures and to compare the risks of NBMs to their (clinical) benefits, based on efficacy, quality and cost criteria, in order to inform robust risk management decision-making.

Course of explosion behaviour of metallic powders - From micron to nanosize

This work presents an overview about the explosion behaviour of metallic powders from micron to nanosize. Aluminium, magnesium, titanium, iron and zinc were considered and their explosion safety parameters were analysed as a function of their mean primary particle size either determined by BET measurements, particle size distribution. To depict the course of explosion behaviour for these metals, extensive literature review has been performed and additional experimental tests were also performed. Generally, decreasing the particle size in a metallic powder leads to a higher explosion severity. It appears that this statement is true till a critical diameter below which the explosion severity (p_max, dp/dt_max) decreases for all the considered powders. This critical size can be explained by theoretical considerations on the nature of thermal transfer in the flame, namely by analysing the Cassel model. Finally, semi-empirical models were also developed for aluminium to highlight the specific micrometre and nanometre behaviour and the influence of turbulence, particle burning time, diameter and concentration. The influence of these key parameters needs to be further assessed in a future work in order to better understand the mechanisms involved and to extend the scope to other powdered materials.

Ignition and explosion risks of nanopowders

Characterization methods with regard to nanopowder flammability and explosivity are presented and illustrated for few nanopowders. Analytical models are developed in order to explain the dependency of the combustion times on the particle diameter. Experimental evidence shows that there exists, for carbonaceous and metallic materials, mainly two combustion regimes that are either kinetically controlled, for small size particles, or diffusion controlled, for large size particles. From the experimentally measured combustion data of those materials, the dependencies of the ignition temperature and the minimal explosive concentration (MEC) with regard to the particle size have been analyzed. We found that the two combustion regimes yield two different tendencies with respect to the particle size. Overall, it is found that as the particle size decreases, minimum ignition temperature (MIT) and minimum ignition energy (MIE) decrease, indicating higher potential inflammation and explosion risks for the use of nanopowders. By contrast, the minimal explosion concentration (MEC) did not show strong variations as the particle size decreases. Rather, a theoretical plateau is observed, which was experimentally confirmed. We also observed that carbon nanopowders exhibit a low propensity to explode while metallic nanopowders can be very reactive, thus delineating high potentials for explosion risks in manufacturing facilities.

[Smoking in professional soccer players in France]

An enquiry was conducted to determine the smoking habits of coaches and professional soccer players in the first and second division of the French championship in 1993 and 1994. The rate of response was 31% for coaches (36 responded) and 54% for players (257 responded). Among the coaches, 19% were smokers, 14% were ex-smokers and 67% were non-smokers; for players, the rates were 36%, 3% and 71% respectively. The percentage of smokers was higher in second division players (31%) than in first division players (20%). Forty percent smoked less than 6 cigarettes a day. Fifty-eight percent of the coaches and 39% of the players thought that smoking and sports were compatible. This study shows that even the highest level sports are not spared from the effect of smoking. Other reports of similar smoking habits have been reported in other sports in France. The image of athletes who smoke given by the media is in contradiction with the national French policy forbidding tobacco advertising in stadiums.

[Occupational asthma to metabisulfites . Three cases]

Sulfites are compounds which are mainly used in the agricultural, food and pharmaceutical industry as preservatives. The possibility of manifestations of acute hypersensitivity appearing after the ingestion or inhalation of sulfites has already been described several times, over the past twenty years. Amongst these manifestations and indeed the one that is most often present is bronchospasm, which can sometimes be severe. A few cases of occupational intolerance through contact eczema to sulfites have also been published. The idea of occupational asthma to metabisulphates is, on the other hand, extremely recent; its legal recognition only dates back to 1989. The authors present three new cases of occupational asthma to metabisulphites stressing the value of a specific provocation test and the different hypotheses for the pathogenesis of the disorder are reviewed. Preventative measures are always preferable to avoid the development of severe occupational asthma. In all cases, notification of occupational asthma is necessary.

[A metastatic neuroendocrine tumor with exceptional outcome!]

INTRODUCTION

Neuroendocrine tumors are rare, with poor prognosis when not or poorly differentiated.

EXEGESIS

The authors report the case of a patient who presented with a metastatic poorly differentiated neuroendocrine tumor that was resistant to chemotherapy. The different sites of the carcinoma were lung, pancreas, kidney and lymph nodes. The patient received no treatment and complete spontaneous remission appeared after 21 months. This remission has been lasting for five years.

CONCLUSION

It is the first case of spontaneous remission of a metastatic poorly differentiated neuroendocrine tumor. The evolution and classical sites of neuroendocrine tumors are reviewed. Renal metastasis is also unusual. This report illustrates the fact that neuroendocrine tumors are heterogeneous.

Tuberculous pseudo-aneurysm of the descending thoracic aorta

A tuberculous pseudo-aneurysm of the thoracic descending aorta was found in a 57 year-old female with haemoptysis three months after successful chemotherapy for a miliary tuberculosis. After aortic angiography, the aneurysm was resected and the aorta was repaired with a Dacron prosthetic graft. The patient is doing well one year after the operation.

Tuberculous pseudo-aneurysm of the descending thoracic aorta

A tuberculous pseudo-aneurysm of the thoracic descending aorta was found in a 57 year-old female with haemoptysis three months after successful chemotherapy for a miliary tuberculosis. After aortic angiography, the aneurysm was resected and the aorta was repaired with a Dacron prosthetic graft. The patient is doing well one year after the operation.

[Peripheral bronchopulmonary cancers. Diagnostic efficiency of fibroscopic samples. Prospective study on 561 patients]

The purpose of this french multicentric study was to evaluate the diagnostic accuracy of samples collected by fibroscopy in peripheral lung cancer with normal endoscopy. Five hundred and sixty-one patients entered the study; a tumour had been diagnosed in 350 of them (62 p. 100). Among these 350 patients, 147 were examined with the help of a light-amplifier screen, and a positive diagnosis was made in 97 (66 p. 100). Guided sample collection in the pathological area (biopsy, brushing, transcatheter aspiration) proved much more rewarding than unguided sample collection (biopsy of the bronchus, simple aspiration or cytology of 3-day sputum): 45 p. 100 positive results versus 18 p. 100 (P less than 0.001). However, sputum cytology still had good diagnostic value since it provided by itself the diagnosis in 14 p. 100 of the cases. Results were significantly inferior in tumours less than 3 cm in diameter.